---
title: "Why Is Blood Cancer Focused Moleculin Biotech Stock Trading More Than 400% On Thursday?"
date: "2025-02-14 02:19:02"
summary: "Moleculin Biotech received FDA guidance reducing its Phase 3 trial size for Annamycin in AML. First unblinding is expected in late 2025, with another in 2026."
categories:
  - "benzinga"
lang:
  - "en"
translations:
  - "en"
tags:
  - "benzinga"
menu: ""
thumbnail: "https://www.benzinga.com/files/images/story/2025/02/13/MBRX.png"
lead: ""
comments: false
authorbox: false
pager: true
toc: false
mathjax: false
sidebar: "right"
widgets:
  - "search"
  - "recent"
  - "taglist"
---

Moleculin Biotech received FDA guidance reducing its Phase 3 trial size for Annamycin in AML. First unblinding is expected in late 2025, with another in 2026.

[benzinga](https://www.benzinga.com/general/biotech/25/02/43705967/why-is-blood-cancer-focused-moleculin-biotech-stock-trading-more-than-400-on-thursday)
